J&J Raises Underlying Guidance After Strong Q4, but Legal Risks Linger

This post was originally published on this site

https://i-invdn-com.akamaized.net/news/LYNXNPEC1N1CT_M.jpg
© Reuters. J&J Earnings Beat, Revenue Misses In Q4© Reuters. J&J Earnings Beat, Revenue Misses In Q4

Investing.com – Johnson & Johnson (NYSE:) raised its guidance for underlying earnings and revenue after a strong fourth quarter on Wednesday but was unable to stop reported earnings slumping due to costs related to opioid- and talc-related lawsuits.

The company announced fourth-quarter of $1.88 a share for the quarter, 1c ahead of forecasts, but reported earnings tumbled by 54% to only 66c. Revenue also fell short of forecasts slightly at $20.75 billion.

EPS were down from $1.97 a year ago, while revenue edged up from $20.39 billion.

The company now expects underlying earnings of a range between $8.62 and $8.67 for 2019, up from a range of $8.53-$8.63 previously. Chief executive Alex Gorsky pointed to “underlying growth in Pharmaceuticals and Medical Devices, as well as continued optimization in our Consumer business” as the reasons.

However, J&J warned that it can’t give forecasts for GAAP line items such as net profit because it is “unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort.”

The outlook still threatens to be a drag on its performance in 2020, according to Investing.com analyst Haris Anwar.

“It’s tough for investors to focus on J&J’s fundamentals when the company is facing thousands of lawsuits in the U.S. over product safety and marketing practices for a range of products including baby powder and opioids,” Anwar said. “In addition to these legal issues, there is a good amount of political uncertainty related to the U.S. presidential election that makes healthcare stocks a risky trade in 2020.”

J&J (NYSE:) stock hit a new record high on Tuesday and finished up 2.3% for the year to date.

J&J follows other major Healthcare sector earnings this month

On October 31, 2019, Novocure Ltd reported third quarter EPS of $0.02 on revenue of $92.06M, was in comparison with a forecasts for EPS of $-0.04 on revenue of $86.94M.

ABIOMED earnings beat analysts’ expectations on January 13, with third quarter EPS of $1.09 on revenue of $221.6M. Investing.com analysts forecast EPS of $1.07 on revenue of $226.67M

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Add Comment